tradingkey.logo

Tonix Pharmaceuticals Announces First Patient Dosed In Phase 2 Oasis Study Of TNX-102 SL For Reduction Of Acute Stress Reaction

ReutersMay 21, 2025 11:20 AM

- Tonix Pharmaceuticals Holding Corp TNXP.O:

  • TONIX PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 OASIS STUDY OF TNX-102 SL FOR REDUCTION OF ACUTE STRESS REACTION

  • TONIX PHARMACEUTICALS HOLDING CORP - TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI